Home/Filings/4/0002007919-24-000045
4//SEC Filing

Lappe Mark 4

Accession 0002007919-24-000045

CIK 0002007919other

Filed

Sep 9, 8:00 PM ET

Accepted

Sep 10, 5:00 PM ET

Size

11.5 KB

Accession

0002007919-24-000045

Insider Transaction Report

Form 4
Period: 2024-09-06
Lappe Mark
DirectorChief Executive Officer
Transactions
  • Purchase

    Common Stock

    2024-09-06$15.29/sh+26,000$397,540647,548 total(indirect: By Trust)
  • Purchase

    Common Stock

    2024-09-09$15.21/sh+9,500$144,495657,048 total(indirect: By Trust)
  • Purchase

    Common Stock

    2024-09-10$15.19/sh+8,500$129,115665,548 total(indirect: By Trust)
Holdings
  • Common Stock

    (indirect: By IRA)
    54,865
  • Common Stock

    (indirect: By Trust)
    165,000
Footnotes (5)
  • [F1]The shares were purchased in multiple transactions at prices ranging from $15.04 to $15.70, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
  • [F2]These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust.
  • [F3]The shares were purchased in multiple transactions at prices ranging from $15.08 to $15.50, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
  • [F4]The shares were purchased in multiple transactions at prices ranging from $15.01 to $15.26, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
  • [F5]These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust.

Issuer

Inhibrx Biosciences, Inc.

CIK 0002007919

Entity typeother

Related Parties

1
  • filerCIK 0001366074

Filing Metadata

Form type
4
Filed
Sep 9, 8:00 PM ET
Accepted
Sep 10, 5:00 PM ET
Size
11.5 KB